Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study BioPharma DiveThe therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.Clinical DataImmunology & InflammationRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said. Clinical DataImmunology & InflammationRead full story Post navigation Previous: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphomaNext: Alamar, Hemab, Kailera, and Seaport advance IPOs Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026